MagicBean
Vanda Pharmaceuticals Files Imsidolimab BLA With FDA; VNDA Stock Soars In Pre-Market Trading
Vanda Pharmaceuticals Inc. (VNDA) stock demonstrated investor enthusiasm Monday morning, climbing 6.10% to $6.61 per share during pre-market trading on Nasdaq. The optimism stems from the company's decision to file a Biologics License Application with the U.S. Food and Drug Administration seeking approval of imsidolimab for generalized pustular psoriasis treatment, a rare and severe autoinflammatory skin disease.
The regulatory submission represents a significant milestone for Vanda, powered by robust
Vanda Pharmaceuticals Inc. (VNDA) stock demonstrated investor enthusiasm Monday morning, climbing 6.10% to $6.61 per share during pre-market trading on Nasdaq. The optimism stems from the company's decision to file a Biologics License Application with the U.S. Food and Drug Administration seeking approval of imsidolimab for generalized pustular psoriasis treatment, a rare and severe autoinflammatory skin disease.
The regulatory submission represents a significant milestone for Vanda, powered by robust